OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Titel:
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa
Auteur:
Jr, Larry D. Anderson, Shah, Nina Jagannath, Sundar Berdeja, Jesus G. Lonial, Sagar Raje, Noopur Siegel, David S. Lin, Yi Moreau, Philippe Yakoub-Agha, Ibrahim Delforge, Michel Einsele, Hermann Goldschmidt, Hartmut Weisel, Katja Cavo, Michele Reece, Donna E. Rambaldi, Alessandro Truppel-Hartmann, Anna Patel, Payal Huang, Liping Campbell, Timothy B. Hege, Kristen San-Miguel, Jesús F. Munshi, Nikhil C. Oriol, A